All News
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Read Article
How early is early in psoriatic arthritis?
Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment.
Read Article
IV Secukinumab for AxSpa
The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.
Read Article
TM06 @ #ACR23: A Force Awakens
86 yo retired attorney w/ HTN, HLD p/w F, chills
4 mo ago:
- mild MDS on BMBx, cytogen neg
- new rash + Cr rise to 3 mg/dl, resolved w/ pred
3 mo ago: wt loss
1 mo ago: chondritis (ear, nose)
1 wk ago: b/l eye red + pain
DIAGNOSIS?
@RheumNow https://t.co/PdtAxnkXaJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow
We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
Eric Dein ( View Tweet)
Editorial position on the use of AI in publishing. AI cannot be listed as an author ✍️ Smolen J, #ACR23 @RheumNow https://t.co/P2eOmi6W5c
Dr. Antoni Chan ( View Tweet)
TM15 @ #ACR23
26yo pregnant F w/ unilat painful breast mass. US resembled abscess. Resolved on 💉aspirat but recurred post-part b/l despite abx & I&D
Coe Needle Bx: multifocal acute abscess w/ foreign body GC reaction on lymphoplasmacytic mastitis
Diagnosis?
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Prof Schett provides #ACR23 a wonderful, easy to digest, review of how CAR-T works. @RheumNow https://t.co/y5HZVAvvhy
Dr. Rachel Tate ( View Tweet)
Dx: Idiopathic granulomatous mastitis
➡️median age: 30 yo
➡️usually 2yrs after breast feeding
➡️RF: hyperprolactinemia, leads to pro-inflam effect
➡️Extra-mammary manifestat: arthralgia, episcleritis, skin changes mimicking autoimm dz
➡️Tx: steroid + AZA vs MTX
#ACR23 @RheumNow https://t.co/lGT2UUIkoM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Some studies addressing fish oil supplementation in patients w/ SLE
Showed improvement in disease activity but not in serologic activity
#ACR23 @RheumNow https://t.co/ANf8yMUd1b
sheila ( View Tweet)
Read my article on ACR Plenaries: Changing the Practice of Rheumatology #ACR23 @ACRheum @RheumNow @uptoTate @Yuz6Yusof @ericdeinmd
https://t.co/ql851dVzAk
TheDaoIndex KDAO2011 ( View Tweet)
What could CAR-T therapy mean for pts? Dr. Schett reviews 8 SLE pts, data collected since 2021 post 1 CAR-T treatment, & their marked improvement/remission of symptoms by classification criteria. Currently, he is studying a total of 15 pts (SLE, SS, myositis) #ACR23 @RheumNow https://t.co/MyMcF3PwiP
Dr. Rachel Tate ( View Tweet)
Excellent pragmatic RCT, TNF withdrawal in RA
Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4
Supports my practice of generally continuing TNFs long term
Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue
@RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z
Mike Putman EBRheum ( View Tweet)
Vaccination appears to be effective and safe post CAR-T treatment. This sets the stage for better understanding of the patient experience. Dr. Schett #ACR23 @RheumNow https://t.co/OQCNTt5wPh
Dr. Rachel Tate ( View Tweet)
In case you missed it! Watch our ACR Monday Recap of the meeting with me, @RheumNow @EBRheum and @ericdeinmd. #ACR23 @uptoTate https://t.co/GpMdev0Yk7
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abs #2548 showed incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomized to BKZ 160 mg Q4W vs PBO. https://t.co/kBLQnJbTU2 @rheumnow https://t.co/regYgvvCts
Dr. Rachel Tate ( View Tweet)
Bimekizumab is Coming… in 3rd Place
Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis.
https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E
Dr. John Cush RheumNow ( View Tweet)
#ACR23 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/0WXuV3wzzF
Dr. John Cush RheumNow ( View Tweet)
ACR2023 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/qOjSd8vuB3
Dr. John Cush RheumNow ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/jjcnekqVPe
Dr. John Cush RheumNow ( View Tweet)